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A B S T R A C T
Purpose: Hyponatremia is one of the most common adverse effects in patients treated with
oxcarbazepine (OXC). Most patients with OXC-induced hyponatremia are asymptomatic, so the
presence of severe or symptomatic hyponatremia, which requires electrolyte correction or discontinua-
tion of OXC therapy, has more important clinically implications. However, data for OXC-induced severe
and symptomatic hyponatremia are limited.
Methods: We reviewed medical records of all patients with epilepsy who were treated with OXC at the
Seoul National University Hospital. We analyzed serum sodium level results and attempted to identify
correlations between various factors and the frequency of severe and symptomatic OXC-induced
hyponatremia.
Results: Data from a total 1009 patient were examined. The frequency of severe and symptomatic
hyponatremia was 11.1% and 6.8%, respectively. Multivariate analysis revealed that age (P = 0.014, OR
1.014), antiepileptic drug (AED) polytherapy (P = 0.040, OR 1.540), and the concomitant use of diuretics
(P < 0.001, OR 5.597) were independent risk factors for OXC-induced severe hyponatremia. Age
(P = 0.001, OR 1.034) and the concomitant use of diuretics (P = 0.035, OR 2.222) were independent risk
factors for OXC-induced symptomatic hyponatremia. The frequency of OXC-induced symptomatic
hyponatremia that was judged to be clinically signiﬁcant was 2.8% among the total OXC-treated epilepsy
patients.
Conclusion: Our study recommended that serum sodium be monitored regularly in patients taking OXC,
especially in old age, AED polytherapy or concomitant use of diuretics, to assist in the early recognition of
hyponatremia and to increase the awareness of symptoms that might be attributable to this.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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As a keto-analog of carbamazepine (CBZ), oxcarbazepine (OXC)
was developed to improve the side-effect proﬁle of CBZ without
affecting its antiepileptic potency. Many clinical trials have shown
that OXC is a valuable antiepileptic drug (AED) for treating adults
and children with partial seizures, as both monotherapy and
adjunctive therapy.1 Although structurally related to CBZ, OXC has
several clinical advantages, such as more favorable pharmacoki-* Corresponding author at: Department of Neurology, Seoul National University
Hospital, 28, Yongkeun Dong, Chongno Ku, Seoul 110-744, South Korea.
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1059-1311/$ – see front matter  2014 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.11.015netics and better tolerability; however, it is associated with an
increased risk of developing hyponatremia.2,3 OXC-induced
hyponatremia is mostly asymptomatic, but its frequency is highly
variable and has been estimated at 23–73.3%.4 Nonetheless, data
on the frequency and risk factors for clinically important OXC-
induced severe and symptomatic hyponatremia are limited, and
there are few studies on the possible effects of concomitant use of
other AEDs and other drugs for the management of nonepileptic
conditions on the development of hyponatremia.
We conducted this study to examine the frequency of severe
and symptomatic hyponatremia and to identify its risk factors. We
also evaluated the clinical characteristics of patients with
hyponatremic symptoms and the approximate time point of their
onset.vier Ltd. All rights reserved.
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2.1. Study design
We reviewed electronic medical records of all patients with
epilepsy who were treated with OXC at the Seoul National
University Hospital during a 10-year period from January 1, 2002
to December 31, 2011. The current study was approved by the
Institutional Review Board of the Seoul National University
Hospital.
2.2. Patients
Inclusion criteria were as follows: (1) adult patients with
epilepsy aged 18 years or older; (2) history of OXC prescription;
and (3) documentation of serum sodium levels at least once after
OXC therapy. Exclusion criteria were as follow: (1) patients with
disease likely to cause hyponatremia including renal failure,
hypothyroidism, adrenal insufﬁciency; (2) patients with abnormal
creatinine level; (3) patients with taking OXC for nonepileptic
disorders. The baseline characteristics of patients including age,
sex, age at seizure onset, disease duration, dosage of OXC, serum
sodium levels, other concomitant AEDs, and other concomitant
medical drugs.
2.3. Measurement of serum sodium levels and diagnosis of
hyponatremia
A sodium level 134 mEq/L was deﬁned as hyponatremia, and a
level 128 mEq/L was deﬁned as severe hyponatremia.5,6 The
combination of the presence of a sodium level 134 mEq/L and
symptoms caused by reduced sodium led to a deﬁnition of
symptomatic hyponatremia. Hyponatremic symptoms were clas-
siﬁed into mild symptoms (lethargy, headache, dizziness, nausea,
vomiting, restlessness, and disorientation) and signiﬁcant symp-
toms (seizure aggravation, respiratory failure, and death).7
2.4. Comparison of medications
In patients who used OXC together with other AEDs (i.e.,
polytherapy), we analyzed the possible effects of other AEDs,
including valproic acid (VPA), levetiracetam (LEV), topiramate
(TPM), lamotrigine (LTG), zonisamide (ZNS), pregabalin (PGB),
gabapentin (GBP), vigabatrin (VGB), clobazam, phenobarbital (PB)
and phenytoin (PHT) on the development of hyponatremia.
We also assessed the possible effects of concomitant medica-
tions that are commonly prescribed for nonepileptic conditions,
such as aspirin, nonsteroid anti-inﬂammatory drugs (NSAIDs),
tricyclic acid (TCAs), serotonin-selective reuptake inhibitors
(SSRIs), antipsychotics, diuretics, opioids, calcium channel blockers
(CCBs), angiotensin II receptor blockers (ARB) and angiotensin-
converting enzyme inhibitors (ACEI), all of which are also known to
potentially cause hyponatremia.7,8
2.5. Statistical analysis
Statistical analysis was performed using SPSS version 19.0 for
Windows (SPSS Inc., Chicago, IL). First, to compare demographic
and clinical data between the two groups using three comparison
situations (with or without hyponatremia with or without severe
hyponatremia (128 mEq/L), and with or without symptomatic
hyponatremia), categorical variables were assessed using the x2
test, and continuous variables were compared using Student’s t
test. The signiﬁcance level was set at P < 0.05. Subsequently,
variables that reached statistical signiﬁcance were entered into a
binary forward-stepwise analysis. Thus, confounding variableswere controlled. This was followed by the calculation of the odds
ratios (ORs) and 95% CI.
3. Results
Our study included 1344 epilepsy patients who had been
prescribed OXC. 335 patients were excluded for various reasons,
such as absence of sodium level values after OXC treatment or
insufﬁcient follow-up (249 patients, 74.3%), prescription of OXC for
a psychiatric disorder or pain control (45 patients, 13.4%) and
having other medical diseases that caused hyponatremia (41
patients, 12.2%). As a result, 1009 patients were included in the
present analysis. The mean duration of OXC treatment was
1280  1236 (range, 39–4524) days. The mean period between start
of OXC treatments and serum sodium measurements was 1031  984
(range, 7–3427) days. The mean number of measurement serum
sodium level per patients was 8.7  7.5 (range, 1–78) times. The
demographic and clinical data of each group (total number of
patients, number of patients with severe hyponatremia, and number
of patients with symptomatic hyponatremia) are listed in Table 1. The
mean age of the patients was 51.55  20.5 years and the sample
included 565 men (55.9%). The mean age of patients with severe
hyponatremia and symptomatic hyponatremia was 62.35  15.5 and
65.23  14.2 years, respectively. In our series, 112 (11.1%) and 69
(6.8%) patients were assigned to the severe hyponatremia and
symptomatic hyponatremia groups, respectively.
A univariate analysis performed to identify risk factors for
severe hyponatremia (Table 2) revealed that the following
variables reached statistical signiﬁcance: age, AED polytherapy,
number of concomitant drugs, concomitant use of aspirin,
concomitant use of NSAIDs, concomitant use of TCAs, concomitant
use of diuretics, and concomitant use of CCBs. Multivariate analysis
showed that age, AED polytherapy, and concomitant use of
diuretics reached statistical signiﬁcance as risk factors for
developing severe hyponatremia. A univariate analysis that was
performed to identify the risk factors for symptomatic hypona-
tremia (Table 3) revealed that the following variables reached
statistical signiﬁcance: age, number of concomitant drugs, and
concomitant use of diuretics. Multivariate analysis showed that
age and concomitant use of diuretics reached statistical signiﬁ-
cance as risk factors for developing symptomatic hyponatremia.
Among the patients with symptomatic hyponatremia, 41 (4.1%)
had mild symptom and 28 (2.8%) had signiﬁcant symptom.
Signiﬁcant hyponatremic symptoms included seizure aggravation
(26 patients) or respiratory distress (2 patients), and mild
hyponatremic symptoms included lethargy (10 patients), head-
ache (5 patients), dizziness (5 patients), nausea or vomiting (7
patients), altered mentality (8 patients), and abnormal behavior (6
patients). Among the patients with symptomatic hyponatremia,
the mean duration of OXC therapy was 872.03  859.1 (range, 373–
2722) days. Hyponatremic symptoms occurred in 59.4% of patients
within 2 years after initial OXC treatment. Thereafter, the frequency
of symptomatic hyponatremia had relatively even distribution
(Fig. 1).
4. Discussion
Although most cases of OXC-induced hyponatremia are
asymptomatic and can be easily corrected,1,9 severe or symptom-
atic hyponatremia is associated with various types of neurological
damage, including seizures, altered mentality, brain stem hernia-
tion, and death.7 The objectives of the current study were to
estimate the frequency of severe and symptomatic hyponatremia
and to identify risk factors for their development. We also
attempted to examine the clinical presentation and the time of
onset of hyponatremia. In addition, we attempted to identify the
Table 2
Univariate and multivariate analyses of demographic and clinical data between









Age, years 62.35  15.5 50.20  20.6 <0.001
Male, n (%) 59 (52.7) 506 (56.3) 0.481
Age at seizure onset, years 34.80  18.7 31.77  15.8 0.517
Disease duration, years 28.42  13.7 23.61  6.5 0.212
OXC mean dose, mg/day 955.04  534.5 906.03  353.4 0.076
AED polytherapy, n (%) 74 (66.1) 500 (55.7) 0.043
VPA, n (%) 12 (10.7) 182 (20.1) 0.021
LEV, n (%) 19 (17.0) 112 (12.5) 0.231
TPM, n (%) 15 (13.4) 164 (18.3) 0.238
Other medical drugs used, n (%) 75 (67.0) 249 (27.7) <0.001
Aspirin, n (%) 17 (15.2) 55 (6.1) 0.001
NSAIDs, n (%) 11 (9.8) 36 (4.0) 0.010
TCA, n (%) 9 (8.0) 23 (2.6) 0.006
SSRI, n (%) 8 (7.1) 37 (4.1) 0.145
Antipsychotics, n (%) 7 (6.3) 30 (3.3) 0.174
Diuretics, n (%) 32 (28.6) 31 (3.5) <0.001
CCB, n (%) 24 (21.4) 70 (7.8) <0.001
Factors OR 95% CI P value
Multivariate analysis
Age 1.014 1.003–1.026 0.014
AED polytherapy 1.540 1.019–2.327 0.040
VPA 0.547 0.272–1.102 0.092
Other medical drugs used 1.824 0.944–3.523 0.074
Aspirin 1.100 0.529–2.289 0.798
NSAIDs 1.609 0.684–3.788 0.276
TCA 1.849 0.742–4.607 0.187
Diuretics 5.597 2.906–10.779 <0.001
CCB 1.327 0.696–2.531 0.390
Table 1
Demographic and clinical data of the patients that received OXC therapy.
Characteristic Total patients (n = 1009) Patients with severe hyponatremia (n = 112) Patients with symptomatic hyponatremia (n = 69)
Age, years 51.55  20.5 62.35  15.5 65.23  14.2
Male, n (%) 565 (55.9) 59 (52.7) 33 (46.5)
Age at seizure onset, years 27.61  15.6 34.80  18.7 31.99  14.8
Mean sodium level, mEq/L 136.79  5.7 125.19  2.8 125.59  3.2
OXC mean dose, mg/day 911.46  377.7 955.04  534.5 911.62  401.6
OXC monotherapy, n (%) 435 (43.0) 38 (33.9) 26 (36.6)
AED polytherapy, n (%) 576 (57.0) 74 (66.1) 45 (63.4)
Combination AEDs, n 766 82 61
VPA, n (%) 194 (25.3) 12 (14.6) 13 (21.3)
TPM, n (%) 179 (23.4) 15 (18.3) 11 (18.0)
LEV, n (%) 131 (17.1) 19 (23.2) 16 (26.2)
PB, n (%) 56 (7.3) 5 (9.6) 4 (6.6)
LMT, n (%) 46 (6.0) 5 (9.6) 2 (3.3)
PGB, n (%) 46 (6.0) 10 (12.2) 6 (9.8)
VGB, n (%) 37 (4.8) 5 (9.6) 2 (3.3)
PHT, n (%) 28 (3.6) 5 (9.6) 3 (4.9)
GBP, n (%) 20 (2.6) 3 (3.7) 1 (1.6)
ZNS, n (%) 16 (2.0) 2 (2.4) 2 (3.3)
Clobazam, n (%) 13 (1.6) 1 (1.2) 1 (1.6)
Other medical drugs used, n (%) 324 (32.0) 75 (67.0) 47 (66.2)
Combination medical drugs, n 510 136 81
Aspirin, n (%) 109 (21.4) 17 (12.5) 11 (13.6)
NSAIDs, n (%) 47 (9.2) 11 (8.1) 7 (8.6)
TCA, n (%) 32 (6.3) 9 (6.6) 5 (6.2)
SSRI, n (%) 45 (8.8) 8 (5.9) 3 (3.7)
Antipsychotics, n (%) 37(7.3) 7 (5.1) 3 (3.7)
Diuretics, n (%) 63 (12.4) 32 (24.1) 21 (25.9)
Opioids, n (%) 41 (8.0) 14 (10.3) 9 (11.1)
CCB, n (%) 94 (18.4) 24 (17.6) 16 (19.8)
ARB, n (%) 22 (4.3) 4 (2.9) 3 (3.7)
ACEI, n (%) 20 (3.9) 10 (7.4) 3 (3.7)
OXC = oxcarbazepine; AED = antiepileptic drug; VPA = valproic acid; TPM = topiramate; LEV = levetiracetam; PB = phenobarbital; LTG = lamotrigine; PGB = pregabalin;
VGB = vigabatrin; PHT = phenytoin; GBP = gabapentin; ZNS = zonisamide; NSAID = nonsteroid anti-inﬂammatory drug; TCA = tricyclic acid; SSRI = selective serotonin reuptake
inhibitor; CCB = calcium channel blocker; ARB = angiotensin II receptor blocker; ACEI = angiotensin-converting enzyme inhibitor.
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conditions, known to be potential risk factors for the development
of hyponatremia, which increased the risk of OXC-induced
hyponatremia in patients with epilepsy.
One previous study demonstrated that the degree of change in
serum sodium concentration was signiﬁcantly negatively corre-Table 3
Univariate and multivariate analyses of demographic and clinical data between









Age, years 65.23  14.3 55.35  16.2 <0.001
Male, n (%) 33 (46.5) 133 (55.0) 0.225
Age at seizure onset, years 36.11  19.4 32.89  13.8 0.644
Disease duration, years 25.22  18.7 26.64  11.4 0.199
OXC mean dose, mg/day 911.62  401.6 952.09  444.7 0.056
AED polytherapy, n (%) 43 (62.3) 165 (68.2) 0.474
VPA, n (%) 13 (18.8) 49 (20.2) 0.740
LEV, n (%) 16 (23.2) 37 (15.3) 0.207
TPM, n (%) 11 (15.9) 44 (18.2) 0.724
Other medical drugs used, n (%) 47 (67.0) 109 (45.0) 0.002
Aspirin, n (%) 11 (15.9) 25 (10.3) 0.289
NSAIDs, n (%) 7 (10.1) 20 (8.2) 0.810
Diuretics, n (%) 21 (30.4) 26 (10.7) <0.001
Opioids, n (%) 9 (13.0) 18 (7.4) 0.225
CCB, n (%) 16 (23.2) 31 (12.8) 0.058
Factors OR 95% CI P value
Multivariate analysis
Age 1.034 1.014–1.055 0.001
Other medical drugs used 1.272 0.662–2.444 0.469
Diuretics 2.222 1.058–4.666 0.035
Fig. 1. Period distribution between starting OXC treatment and hyponatremic
symptoms onset among 69 symptomatic hyponatremic patients.
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induced hyponatremia occurred in a dose-dependent man-
ner.3,10,11 However, another study failed to show a dose-dependent
relationship in the occurrence of OXC-induced hyponatremia.5 In
our study, the daily mean dose of OXC was not a risk factor for the
occurrence of severe hyponatremia (p = 0.076), or symptomatic
hyponatremia (P = 0.056); however, as described in other
reports,3,6,10,11 co-administration of OXC with other AEDs in-
creased the risk of OXC-induced severe hyponatremia (P = 0.043).
Moreover, the use of OXC in conjunction with non-AED drugs also
led to a signiﬁcant increase in the risk of developing OXC-induced
severe (P < 0.001) and symptomatic (P = 0.002) hyponatremia.
Most cases of OXC-induced severe or symptomatic hyponatremia
can be corrected with dose reduction or drug discontinuation and
ﬂuid restriction.12 Rarely, patients might be at increased risk of
developing a permanent disability if there is a delay in the diagnosis
and treatment of OXC-induced severe or symptomatic hyponatre-
mia. The data available on OXC-induced symptomatic hyponatremia
are very limited. One small study reported that ﬁve out of 18 (27.8%)
patients with OXC-induced hyponatremia had hyponatremic
symptoms, including headache (n = 1), general malaise (n = 3), gait
disturbance (n = 1), and somnolence (n = 1).6 The present study
identiﬁed 28 patients with signiﬁcant symptomatic OXC-induced
hyponatremia, most of whom experienced seizure recurrence and
two of whom suffered from respiratory distressed. The results of our
study suggest that when epilepsy patients treated with OXC show
seizure aggravation, abnormal behavior, or altered mentality
without deﬁnite provoking factors, OXC-induced hyponatremia
should be considered as a possible cause.
Although there is no known biochemical mechanism connect-
ing VPA treatment and hyponatremia, VPA has been reported to
induce hyponatremia in several cases.13,14 LEV has been docu-
mented in association with OXC-induced hyponatremia5 and LTG
has been documented in associated with hyponatremia15 however,
our study found no association between these speciﬁc AEDs and
OXC-induced severe and symptomatic hyponatremia.
Epilepsy is may be a lifelong condition, and many other
neurological disorders, such as stroke and dementia, become
important causes of elderly-onset epilepsy. Therefore, many
patients are likely to be exposed to a range of concomitant drugs,
in addition to AEDs.16 In our study, old age and the use of other
drugs for medical conditions increased the risk of OXC-induced
hyponatremia, especially aspirin, NSAIDs, CCBs, TCAs, and
diuretics. In particular, old age and diuretics were more important
independent risk factors for OXC-induced severe and symptomatic
hyponatremia. Therefore, when clinicians prescribe OXC to elderly
patients with vascular risk factors, they should provide appropriateinformation regarding the possible risk of developing hypona-
tremia and should check the serum sodium level regularly. The
time of onset of hyponatremia after the use of OXC begins is
another issue in patients receiving OXC treatment. One study
showed that OXC-induced hyponatremia occurred 3 weeks after
starting OXC,17whereas another prospective study did not note the
time of onset of hyponatremia, despite the serial measurement of
serum sodium levels (once every 3 months).6 In the current study,
because we conducted a retrospective review of medical records,
we were not able to conﬁrm the time of the onset of OXC-induced
hyponatremia. If it is assumed that serum sodium levels were
measured at the time of onset of symptomatic hyponatremia, it is
possible to estimate the period between starting OXC treatment
and the onset of the hyponatremic symptoms. Based on this
analysis, patients with symptomatic hyponatremia were treated
with OXC for a mean duration of nearly 2.5 years before symptom
onset. The distribution of the time of onset of OXC-induced
symptomatic hyponatremia was within 2 years in approximately
59.4% of our clinical series of patients. However, this analysis does
not take account of any delays between symptom onset,
presentation to the clinician and measurement of serum sodium.
Our study has several limitations. First, as this study was
performed retrospectively, we did not check the basal sodium
levels before OXC use. Preexisting or unassociated with OXC
hyponatremic patients are likely to have been included. So, we
excluded patients with disease likely to cause hyponatremia
including renal failure, hypothyroidism, and adrenal insufﬁciency.
Second, we did not consider the relationship between OXC-
induced hyponatremia and the serum levels of MHD, which is the
main pharmacologically active metabolite of OXC. Third, we
determined hyponatremic symptoms based on medical records. It
is possible that symptoms, especially mild ones, were not caused
purely by hyponatremia. Fourth, there may have been a time lag
between symptom onset, presentation to the clinician and
measurement of serum sodium.
5. Conclusion
Nevertheless, we believe that our study has useful clinical
applications because it suggests that clinicians should provide
adequate information to patients regarding the possibility and
common symptoms of OXC-induced hyponatremia before pre-
scribing this drug and should perform serial monitoring of serum
sodium levels, especially in the elderly and those who take OXC
with concomitant AEDs or other medications. And then, more to
ensure a clear association of hyponatremia with OXC, further
prospective study is needed.
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